INTRODUCTION
============

The increase in antibiotic-resistant bacteria has revived the interest in plant products as alternative/adjunct antimicrobial agents to control pathogenic micro-organisms ([@B3]; [@B10]; [@B11]). A major group of plant antimicrobial compounds is represented by essential oils, which are complex mixtures of volatile secondary metabolites. They are used in the food industry because of their preservative potency against food-borne pathogens---thanks to their antimicrobial, antibacterial, and antifungal properties. Besides antimicrobial activity, essential oils and their components can act in synergy with some antibiotics, enhancing their antimicrobial activity ([@B13]). The phenolic monoterpene carvacrol \[2-Methyl-5-(1-methylethyl) phenol, isomeric with thymol\] is a major component of the essential oils of plants of the Labiatae family, including *Origanum* and *Thymus*, which are commonly used as seasoning and in traditional medicine since ancient times ([@B16]). Carvacrol has been classified as GRAS (Generally Recognized As Safe) and approved for food use ([@B5]; [@B11]; [@B6]). Beside anti-inflammatory, antioxidant, antitumor, analgesic, anti-hepatotoxic, and insecticidal properties, several studies have demonstrated that carvacrol has antimicrobial properties ([@B11]). Findings regarding the latter properties are the subject of a recent review ([@B11]). The antibacterial action of carvacrol, which is stronger against Gram-positive than Gram-negative bacteria, principally relies on bacterial membrane damage; it results in dissolution of the proton motive force and subsequent reduction in ATP synthesis that lead to reduction in other energy-dependent cell processes, including synthesis of enzymes and toxins ([@B16]). In particular, carvacrol has extensively been tested as an antimicrobial agent in food to control Gram-positive and Gram-negative pathogens, including *Bacillus cereus*, *Enterococcus faecalis*, *Listeria monocytogenes*, *Staphylococcus aureus*, *Escherichia coli* O157:H7, *Pseudomonas fluorescens*, *Salmonella typhimurium*, *Vibrio cholerae*, and *V. vulnificus* ([@B11]; [@B13]). The ability of carvacrol to exert synergistic effects in combination with a number of antibiotics, including macrolides, has been recently reported ([@B13]).

Erythromycin and related molecules are the second-line drugs used to treat pharyngotonsillitis and other infections caused by *Streptococcus pyogenes* \[Group A streptococci (GAS)\], an important human pathogen. GAS cause a variety of clinical manifestations ranging from non-invasive disease, such as pharyngitis and impetigo, to more severe, invasive infections including necrotizing fasciitis, sepsis, toxic shock-like syndrome, and post-streptococcal *sequelae* such as acute rheumatic fever, rheumatic heart disease, and glomerulonephritis ([@B4]). In particular, GAS are the most common bacterial cause of pharyngotonsillitis in children. Over the past decades erythromycin resistance in GAS has emerged in several countries, including Italy ([@B12]; [@B9]). At present, it has fallen dramatically in Europe and America, while rates \>90% have recently been reported in China ([@B1]; [@B14]). Several genes are responsible for erythromycin resistance in GAS ([@B8]). An eﬄux mechanism encoded by different macrolide eﬄux (*mef*) genes causes resistance to 14- and 15-membered macrolides (M phenotype); in contrast, ribosomal modification by erythromycin resistance methylase (*erm*) genes causes co-resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics. MLS resistance is constitutive when it is encoded by the *erm*(B) gene (cMLS phenotype); it is inducible, i.e., expressed only in presence of the antibiotic, when it is encoded by the *erm*(TR) or the variant *erm*(B) gene (iMLS phenotype). An association between erythromycin resistance and ability to invade and survive within human respiratory cells has been documented in Italy among GAS isolated from children with pharyngotonsillitis ([@B7]): these strains may escape β-lactams because of intracellular location and macrolides---which unlike β-lactams enter eukaryotic cells and are active in intracellular compartments---because of resistance, resulting in difficulty of eradication and recurrent pharyngitis.

In this study, we evaluated the antibacterial activity of different essential oils and of carvacrol, alone and in combination with erythromycin, against erythromycin-resistant GAS isolated from children with pharyngotonsillitis in Italy.

MATERIALS AND METHODS {#s1}
=====================

GAS STRAINS AND GROWTH MEDIA
----------------------------

Test strains were 32 erythromycin-resistant \[Mininum Inhibitory Concentration (MIC) ≥1 μg/mL\] GAS strains isolated from children with pharyngotonsillitis in a nationwide survey in Italy ([@B23]; **Table [1](#T1){ref-type="table"}**). Erythromycin-resistant GAS isolates were genotypically and phenotypically heterogeneous: *erm*(TR)/iMLS (*n* = 6); *erm*(B)/iMLS (*n* = 6); *erm*(B)/cMLS (*n* = 8); *mef*(A)/M (*n* = 12). The strains had previously been investigated for the association between erythromycin resistance and ability to enter and persist inside human respiratory A549 cells ([@B7]; [@B22], [@B21]); they had also been typed at the molecular level ([@B22], [@B21]). Each of the 32 strains included in the study represents a clone identified among Italian erythromycin-resistant GAS. Blood agar base (BAB) supplemented with 5% sheep blood, Müller-Hinton agar (MHA) supplemented with 5% sheep blood, Müller-Hinton cation-adjusted broth (CAMHB) supplemented with 3% laked sheep blood, and brain heart infusion broth (BHIB; Oxoid, Basingstoke, UK) were used throughout the study. Isolates were maintained in glycerol at -70^∘^C and sub-cultured twice on BAB before testing.

###### 

Characteristics of erythromycin-resistant GAS, each strain representing an erythromycin-resistant Italian GAS clone.

  Genotype/phenotype of erythromycin resistance (no. of strains)   Mininum Inhibitory Concentration (MIC; μg/mL)   Fractional Inhibitory Concentration (FIC) Index                                          
  ---------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------- ------ ---- -------- -------- -------- --------
  ***erm*(TR)/iMLS (*n* = 6)**                                                                                                                                                                              
  SP1900^d^                                                        256                                             128                                               4      32   0.0156   0.2500   0.2656   
  SP1161                                                           8                                               64                                                1      8    0.1250   0.1250   0.2500   
  SP55                                                             8                                               128                                               0.5    32   0.0625   0.2500   0.3125   
  SP1160                                                           16                                              128                                               4      8    0.2500   0.0625   0.3125   
  SP4502                                                           64                                              128                                               16     8    0.2500   0.0625   0.3125   
  11613                                                            8                                               64                                                2      16   0.2500   0.2500   0.5000   
  ***erm*(B)/iMLS (*n* = 6)**                                                                                                                                                                               
  SP1188                                                           512                                             128                                               0.5    32   0.0009   0.2500   0.2509   
  11414                                                            512                                             128                                               0.5    32   0.0009   0.2500   0.2509   
  11107                                                            512                                             128                                               1      32   0.0019   0.2500   0.2519   
  SP1181                                                           512                                             128                                               2      32   0.0039   0.2500   0.2539   
  SP114                                                            512                                             128                                               0.5    32   0.0009   0.2500   0.2509   
  SP1189                                                           512                                             64                                                0.25   32   0.0005   0.5000            0.5005
  ***erm*(B)/cMLS (*n* = 8)**                                                                                                                                                                               
  SP2130                                                           512                                             128                                               2      32   0.0039   0.2500   0.2539   
  10039                                                            512                                             128                                               2      32   0.0039   0.2500   0.2539   
  SP9707                                                           512                                             64                                                0.25   32   0.0005   0.5000            0.5005
  SP9103                                                           512                                             64                                                0.25   32   0.0005   0.5000            0.5005
  37014                                                            512                                             64                                                0.25   32   0.0005   0.5000            0.5005
  SP1791                                                           512                                             64                                                0.25   32   0.0005   0.5000            0.5005
  SP1003                                                           512                                             128                                               0.25   64   0.0005   0.5000            0.5005
  SP1070                                                           512                                             128                                               0.25   64   0.0005   0.5000            0.5005
  ***mef*(A)/M (*n* = 12)**                                                                                                                                                                                 
  10911                                                            8                                               64                                                2      16   0.2500   0.2500   0.5000   
  SP9721                                                           16                                              64                                                0.5    16   0.0313   0.2500   0.2813   
  9407                                                             32                                              64                                                8      16   0.2500   0.2500   0.5000   
  SP1180                                                           16                                              128                                               4      32   0.2500   0.2500   0.5000   
  10239                                                            16                                              128                                               4      32   0.2500   0.2500   0.5000   
  SP118                                                            16                                              256                                               0.5    64   0.0313   0.2500   0.2813   
  10244                                                            16                                              128                                               4      32   0.2500   0.2500   0.5000   
  10313                                                            16                                              128                                               4      32   0.2500   0.2500   0.5000   
  SP1013                                                           1                                               128                                               0.25   64   0.2500   0.5000            0.7500
  13962                                                            16                                              128                                               0.5    64   0.0313   0.5000            0.5313
  128--192                                                         16                                              128                                               0.5    64   0.0313   0.5000            0.5313
  SP1951                                                           16                                              128                                               0.03   64   0.0019   0.5000            0.5019
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ANTIMICROBIALS AND SUSCEPTIBILITY TESTS
---------------------------------------

Five different essential oils \[origanum (W282812), thyme (W306401), lavender (W262218), tea tree (W390208), and peppermint (W284815)\], carvacrol (W224502, \>98% purity), and erythromycin (E-5389) were all purchased from Sigma--Aldrich (St. Louis, MO, USA). Essential oils (10 mg/mL stock solutions) were stored in DMSO at -20^∘^C; carvacrol and erythromycin (10 mg/mL stock solutions) were stored in absolute ethanol at -20^∘^C. MIC is defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. MICs of essential oils and carvacrol were determined by agar dilution (in blood-supplemented MHA) and microdilution (in blood-supplemented CAMHB) methods, respectively, as recommended by [@B2] guidelines. All experiments were performed in triplicate.

LIVE/DEAD ASSAY
---------------

Group A streptococci survival in presence of carvacrol was studied by the live/dead assay as described previously ([@B24]) using SYBR Green I (Invitrogen, Eugene, OR, USA) and propidium iodide (Sigma--Aldrich), two nucleic acid dyes differing in their ability to penetrate bacterial cells: bacteria with intact cell membranes stain fluorescent green, whereas those with damaged membranes stain fluorescent red. Briefly, overnight grown streptococci were suspended in 1 mL carvacrol-supplemented BHIB (∼1 × 10^8^ CFU/mL) and incubated for 1, 3, or 24 h at 37^∘^C in 5% CO~2~. After staining with 1 × SYBR Green I and 40 μg/mL propidium iodide, samples were incubated at room temperature for 25 min in the dark, harvested on GTBP filters (Ø = 0.2 μm, Millipore, Billerica, MA, USA), and examined under an epifluorescence microscope (Axioskop 2, Zeiss, Milano, Italy).

CHECKERBOARD TEST
-----------------

Synergy was tested by the checkerboard method, a two-dimensional array of serial concentrations of test compounds, that has been used most frequently to assess antimicrobial combinations *in vitro* ([@B20]). The tested dilutions were based on the MIC of the two substances. The checkerboard test was used as the basis to calculate a Fractional Inhibitory Concentration (FIC) Index ([@B20]) according to the formulas: FIC~A~ = MIC~A+B~/MIC~A~, FIC~B~ = MIC~B+A~/MIC~B~, FIC Index = FIC~A~+FIC~B~. The MIC~A+B~ value is the MIC of compound A in the presence of compound B, and *vice versa* for MIC~B+A~. FIC Index values were interpreted accordingly to Odds ([@B17]): synergy (FIC Index ≤0.5), antagonism (FIC Index \>4.0), and no interaction (FIC Index \>0.5--4.0).

The test was performed in blood-supplemented CAMHB using 96-well microtiter plates containing erythromycin and carvacrol in twofold serial concentrations. Bacterial suspensions were prepared to yield final inocula of ∼5 × 10^5^ CFU/mL. Plates were read after overnight incubation at 37^∘^C in 5% CO~2~. Each test was performed in triplicate. Test results were also represented by isobolograms constructed by plotting synergistic concentrations of carvacrol and erythromycin ([@B15]).

TIME-KILL CURVES
----------------

Time-kill experiments were performed in BHIB in microtiter plates containing different combinations of carvacrol and erythromycin at different sub-MICs. Briefly, streptococci (∼5 × 10^5^ CFU/mL) were placed on microtiter plates, incubated for 24 h at 37^∘^C and read at OD~690~ at 1-h intervals using Multiscan Ascent (Thermo Scientific, Waltham, MA, USA). Controls also included growth in presence of carvacrol and erythromycin alone. All experiments were performed in triplicate.

SEARCH FOR CARVACROL MUTANTS
----------------------------

In these experiments, bacterial cells were grown overnight in BHI agar plates, scraped off, washed once with BHIB, and resuspended to a final concentration of 1 × 10^10^ to 1 × 10^11^ CFU/mL. An aliquot (50 μL) of bacterial suspension was spread on carvacrol-containing BAB plates at 1, 2, and 4 times the MIC. The plates were incubated at 37^∘^C in CO~2~ for 72 h. Experiments were repeated twice.

STATISTICAL ANALYSIS
--------------------

Synergy data were analyzed using Fisher's exact test. Fisher's test was used to evaluate whether the association between phenotype iMLS and synergy in *erm*-carrying strains was significant. Significance was set at *p*-value \< 0.01.

RESULTS
=======

The MICs of origanum and thyme oils ranged from 256 to 512 μg/mL, while those of lavender, tea tree, and peppermint oils ranged from 1024 to \>4096 μg/mL (**Figure [1](#F1){ref-type="fig"}**). The MICs of carvacrol were 64 μg/mL (*n* = 10 strains), 128 μg/mL (*n* = 21 strains), and 256 μg/mL (*n* = 1 strain; **Table [1](#T1){ref-type="table"}**). In the live/dead assay several red cells were detected as early as 1 h after incubation with carvacrol at the MIC (data not shown).

![**Mininum Inhibitory Concentrations (MICs) of five essential oils against GAS strains**.](fmicb-06-00165-g001){#F1}

In the checkerboard assay, 77 different combinations of erythromycin and carvacrol were tested for each strain, ranging from several dilutions below the MIC to twice the MIC. A 2- to 2048-fold reduction of the erythromycin MIC was documented in synergy tests with the checkerboard assay (**Table [1](#T1){ref-type="table"}**). FIC Index values were calculated by considering all combinations of carvacrol and erythromycin in which there was no visible growth. The "best combination" of carvacrol and erythromycin, i.e., the one giving the lowest FIC Index value, was indicated in **Table [1](#T1){ref-type="table"}**. FIC Index values ranged from 0.25 to 0.75 (**Table [1](#T1){ref-type="table"}**). Synergy (FIC Index ≤0.5) was detected in 21/32 strains (65.6%) and no interaction (FIC Index \>0.5) in the remaining 11 strains (34.4%); antagonism was never observed. Strains where synergy was detected included all 6 *erm*(TR)/iMLS, 5/6 *erm*(B)/iMLS, 2/8 *erm*(B)/cMLS, and 8/12 *mef*(A)/M isolates. Among *erm*-carrying strains the association between the iMLS phenotype and synergy was very statistically significant (*p* = 0.0044). Strains where no interaction was detected included 8 strains with borderline FIC Index values (0.5005, 0.5019). Isobolographic analysis confirmed a synergistic effect against strains with FIC Index ≤0.5 (**Figure [2](#F2){ref-type="fig"}**) and no interaction against those with FIC Index \>0.5, including those with borderline FIC Index values (data not shown).

![**Checkerboard test and isobolograms. (A,B)** strain SP1161 \[Fractional Inhibitory Concentration (FIC) Index = 0.2500\]; **(C,D)** strain 10911 (FIC Index = 0.5000). Shading, visible growth. CAR, carvacrol; ERY, erythromycin.](fmicb-06-00165-g002){#F2}

Synergy was also examined in 23 strains (18 strains with FIC Index ≤0.5 and 5 strains with FIC Index \>0.5) using 24-h time-kill curves in presence of carvacrol and erythromycin. These findings confirmed the checkerboard data in 13/18 strains with FIC Index ≤0.5 (8/9 iMLS, 1/1 cMLS, and 4/8 M; **Figure [3A](#F3){ref-type="fig"}**), and in 4/5 strains with FIC Index \>0.5 (1 cMLS, and 3 M; **Figure [3B](#F3){ref-type="fig"}**). The time-kill curves of the two strains with borderline FIC Index values (SP1951, FIC Index 0.5019; and SP1189, FIC Index 0.5005) indicated a lack of interaction (**Figures [3C,D](#F3){ref-type="fig"}**), even though synergy was seen in strain SP1189 in the first 18 h (**Figure [3D](#F3){ref-type="fig"}**). The discrepancy between checkerboard and time-kill data may depend on the media (with/without blood) and/or growth conditions (with/without CO~2~) ([@B17]).

![**Time-kill curves. (A)** strain SP1900 (FIC Index = 0.2656). **(B)** SP1013 (FIC Index = 0.7500). **(C)** SP1951 (FIC Index = 0.5019). **(D)** SP1189 (FIC Index = 0.5005). CAR, carvacrol; ERY, erythromycin.](fmicb-06-00165-g003){#F3}

No carvacrol-resistant mutants were obtained in single-step resistance selection experiments using strains SP2130, SP1188, SP1900, and 10239.

DISCUSSION
==========

One of the alternative strategies to fight antibiotic-resistant bacteria is the use of natural antimicrobial substances such as plant essential oils and their components. Another possibility is to combine existing antibiotics with phytochemicals to enhance the efficacy of antibiotics. Among others, essential oils from *Thymus vulgaris* and *Origanum vulgare* contain carvacrol and thymol, whose antibacterial activity and synergistic effect in combination with antibiotics against food-related bacteria have been demonstrated ([@B11]; [@B13]).

In this study, the antimicrobial activity of five essential oils from different plants was tested against pharyngeal GAS isolates, all erythromycin-resistant and cell-invasive strains. The antimicrobial activity of thyme and origanum oils was high, with MICs much lower than those of lavender, mint, and tea tree oils. Since carvacrol is a major component of thyme and origanum essential oils, we decided to test the susceptibility of GAS strains to carvacrol. Our findings demonstrated a high activity of carvacrol against GAS, with MICs lower than those reported for other Gram-positive bacteria ([@B11]). A bactericidal action of carvacrol, probably through membrane damage, was suggested by the live/dead assay. Attempts to select carvacrol-resistant mutants were unsuccessful, suggesting that carvacrol is not prone to the development of resistance in GAS.

To our knowledge the synergistic activity of carvacrol and antibiotics against GAS has never been investigated, with the exception of a recent study of a single *erm*(B) collection strain ([@B18]). Carvacrol in combination with erythromycin showed a synergistic action against tested GAS isolates; antagonism was never observed.

Interestingly, synergy was highly significant (*p* \< 0.01) in iMLS strains, in which erythromycin resistance is only expressed in presence of an inducing sub-inhibitory concentration of the antibiotic. The molecular basis of the synergy deserves further investigation; an interference with the expression of the inducible methyl-transferases gene or inhibition of the enzyme itself might be involved in carvacrol's synergistic action against iMLS GAS strains.

Overall, results of the current study suggest a potential use of origanum and thyme essential oils and of carvacrol against GAS. Moreover, the evidence of a synergism between erythromycin and carvacrol suggest a possible re-use of erythromycin against erythromycin-resistant GAS. In particular, carvacrol might be useful against those GAS strains which combine erythromycin resistance and the ability to invade and survive within human respiratory cells ([@B7]), resulting in difficulty of eradication and recurrent pharyngitis. With more knowledge of the mechanism underlying the synergism it may be possible to develop safe drug combinations.
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